MX2023008106A - Tratamiento de metástasis cerebrales y metástasis del cns usando iludinas o hidroxilureametil acilfulveno. - Google Patents

Tratamiento de metástasis cerebrales y metástasis del cns usando iludinas o hidroxilureametil acilfulveno.

Info

Publication number
MX2023008106A
MX2023008106A MX2023008106A MX2023008106A MX2023008106A MX 2023008106 A MX2023008106 A MX 2023008106A MX 2023008106 A MX2023008106 A MX 2023008106A MX 2023008106 A MX2023008106 A MX 2023008106A MX 2023008106 A MX2023008106 A MX 2023008106A
Authority
MX
Mexico
Prior art keywords
metastases
acylfulvene
hydroxylureamethyl
illudins
treatment
Prior art date
Application number
MX2023008106A
Other languages
English (en)
Inventor
Aditya Kulkarni
Kishor Bhatia
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of MX2023008106A publication Critical patent/MX2023008106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta solicitud describe métodos para tratar un cáncer que ha hecho metástasis en el cerebro de un sujeto usando una cantidad terapéuticamente efectiva de hidroxiureametil acilfulveno. Además, se describen composiciones farmacéuticas que tienen hidroxiureametil acilfulveno y un portador, diluyente, excipiente, o una combinación de estos farmacéuticamente aceptable.
MX2023008106A 2021-01-08 2022-01-10 Tratamiento de metástasis cerebrales y metástasis del cns usando iludinas o hidroxilureametil acilfulveno. MX2023008106A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135370P 2021-01-08 2021-01-08
PCT/US2022/070126 WO2022150851A2 (en) 2021-01-08 2022-01-10 Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene

Publications (1)

Publication Number Publication Date
MX2023008106A true MX2023008106A (es) 2023-09-21

Family

ID=82358796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008106A MX2023008106A (es) 2021-01-08 2022-01-10 Tratamiento de metástasis cerebrales y metástasis del cns usando iludinas o hidroxilureametil acilfulveno.

Country Status (9)

Country Link
US (1) US20240325328A1 (es)
EP (1) EP4274662A2 (es)
JP (1) JP2024505392A (es)
KR (1) KR20230130044A (es)
CN (1) CN116847834A (es)
AU (1) AU2022205447A1 (es)
CA (1) CA3204446A1 (es)
MX (1) MX2023008106A (es)
WO (1) WO2022150851A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024187196A1 (en) * 2023-03-09 2024-09-12 Lantern Pharma Inc. Method for treating renal cell carcinoma or cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2015157578A2 (en) * 2014-04-10 2015-10-15 Af Chemicals, Llc Affinity medicant conjugates
RU2728796C2 (ru) * 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
CA3116552A1 (en) * 2018-10-14 2020-04-23 Lantern Pharma Inc. Methods for the treatment of solid tumor cancers using illudins and biomarkers

Also Published As

Publication number Publication date
US20240325328A1 (en) 2024-10-03
KR20230130044A (ko) 2023-09-11
CN116847834A (zh) 2023-10-03
CA3204446A1 (en) 2022-07-14
WO2022150851A3 (en) 2022-09-15
EP4274662A2 (en) 2023-11-15
WO2022150851A2 (en) 2022-07-14
AU2022205447A1 (en) 2023-07-27
JP2024505392A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
NZ771328A (en) Splicing modulator antibody-drug conjugates and methods of use
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
MX2024009727A (es) Terapias de combinacion.
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
PH12019501896A1 (en) Therapeutic dendrimers
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2018012719A (es) Ram negativas para tratar la dermatitis atopica.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
CR20240144A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
ECSP21034596A (es) 2,3,5-trimetil-6-nonilclohexa-2,5-diena-1,4-diona para suprimir y tratar alfa-sinucleinopatías, tauopatías y otros trastornos
MX2023008106A (es) Tratamiento de metástasis cerebrales y metástasis del cns usando iludinas o hidroxilureametil acilfulveno.
NZ771735A (en) Compound for treatment or prevention of liver diseases
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
EA202190171A1 (ru) Применение грамотрицательных видов для лечения атопического дерматита
PH12019500043A1 (en) Novel benzenesulfonamide compositions for treatment of malignant pleural effusions
MX2024005855A (es) Procedimientos para tratar el cancer.
WO2023086220A3 (en) Papd5 inhibitors and methods of use thereof
WO2020231739A3 (en) Compounds and methods for treating cancer
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
MX2023008375A (es) Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer